Functional assays were conducted to assess the impact of COL1A2 expression on docetaxel sensitivity in HR+/HER2- breast cancer cells.<h4>Results</h4>PCCLs derived from HR+/HER2- breast cancer exhibited heterogeneous sensitivity to taxanes, including docetaxel. This evidence concerns the gene COL1A2 and breast carcinoma.